AZD5438 in Patients With Advanced Solid Malignancies

Completed · Phase 1

Conditions studied: Neoplasms

In brief

Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.

Key facts

Study ID

NCT00088790

Run by

AstraZeneca

Starts

2004-07-01

Expected to finish

2005-12-01

Last updated by the study team

2011-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced solid malignancy
• Cancer refractory to standard treatments or for which no standard therapy exits

You may not qualify if…

• Radiotherapy within 3 weeks of the start of treatment
• Investigational product within the last 3 weeks
• Systemic cytotoxic anti-cancer therapy within the last 3 weeks
• Any significant clinical disorder that makes it undesirable for the patient to participate

Where it is running

• Research Site — Boston, Massachusetts, United States
• Research Site — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.